Global Cord Blood Corp
globalcordbloodcorporation.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2022 20-F, filed Aug 16, 2022. Its latest SEC filing is a 6-K from Oct 22, 2026.
20-F for FY2022, filed Aug 16, 2022
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Stores cord blood for expectant parents and families through cord blood banking services in China.
20-F for FY2022, filed Aug 16, 2022The Group receives fees for collecting, testing, freezing and storing of cord blood units. Once the cord blood units are collected, tested…View ↗
Activities targeting prospective parents. We maintain our hospital networks which consist of 434 hospitals in Beijing, Guangdong and…View ↗
The Company’s chief operating decision maker (“CODM”) has been identified as the Chief Executive Officer. The CODM regularly reviews…View ↗
How Did They Make Money?
Customers pay a processing fee when they deliver cord blood, then pay storage fees annually in advance or upfront for the storage period; some pay processing and storage fees in installments. Processing is paid for a completed service, while storage fees cover ongoing storage.
20-F for FY2022, filed Aug 16, 2022The Group receives fees for collecting, testing, freezing and storing of cord blood units. Once the cord blood units are collected, tested…View ↗
The Group recognizes revenues when promised goods or services are transferred to customers in an amount that reflects the consideration…View ↗
Payment of the processing fee upon delivery of the cord blood unit to the Group’s premises for processing and the annual storage fee in…View ↗
Payment of the processing fee upon delivery of the cord blood unit to the Group’s premises for processing and an upfront payment of storage…View ↗
Payment of the processing fee by installment over multiple periods and the annual storage fee in advance at the beginning of each annual…View ↗
CNY 1.2B
-
20-F for FY2022, filed Aug 16, 2022
CNY 1.2B ↗
| Segment | Share | Revenue |
|---|---|---|
|
Processing fees
|
56%
FY2019: 60%
|
Processing fees, FY2022
$109.3M Sources
|
|
Storage fees
|
43%
FY2019: 39%
|
Storage fees, FY2022
$84.8M Sources
|
|
Fees derived from the provision of donated cord blood for transplantation and research and others
|
1.0%
FY2019: 0.9%
|
Fees derived from the provision of donated cord blood for transplantation and research and others, FY2022
$2M Sources
|
Who Were Their Customers?
Expectant parents and families sign agreements for cord blood collection, processing and storage; the company reaches prospective subscribers directly through consultants at collaborating hospitals.
20-F for FY2022, filed Aug 16, 2022The Group receives fees for collecting, testing, freezing and storing of cord blood units. Once the cord blood units are collected, tested…View ↗
Our hospital networks offer us the platforms where a significant portion of our sales and marketing activities are undertaken. We have…View ↗
Activities targeting prospective parents. We maintain our hospital networks which consist of 434 hospitals in Beijing, Guangdong and…View ↗
Did Revenues Turn Into Profits?
Yes. It kept 40.3% of its revenue as net income in FY2022 and turned 47.8% of it into free cash flow.
20-F for FY2022, filed Aug 16, 2022
CNY 608.9MView ↗
20-F for FY2022, filed Aug 16, 2022
CNY 501.1MView ↗
20-F for FY2022, filed Aug 16, 2022
CNY 593.8MView ↗
How Were They Changing?
Grew. Revenue grew 33% in 4 years, from CNY 936.8M in FY2018 to CNY 1.2B in FY2022, about 7% a year.
Who Did They Compete With?
Competes with Vcanbio Cell & Gene Engineering, Shanghai Stem Cell Technology, and Sichuan Neo-life Stem Cell Biotech
20-F for FY2022, filed Aug 16, 2022To date, only seven cord blood banking licenses have been issued by PRC government authorities. We are the operator of the sole licensed…View ↗
Loading...
